European Journal of Cancer最新文献

{"title":"Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment","authors":"Hiroshi Imaoka ,&nbsp;Masafumi Ikeda ,&nbsp;Masato Ozaka ,&nbsp;Kotoe Oshima ,&nbsp;Naohiro Okano ,&nbsp;Satoshi Shimizu ,&nbsp;Hidetaka Tsumura ,&nbsp;Yoshito Komatsu ,&nbsp;Taro Yamashita ,&nbsp;Shigeki Kataoka ,&nbsp;Hiroaki Nagano ,&nbsp;Terumasa Hisano ,&nbsp;Mitsuhito Sasaki ,&nbsp;Satoshi Kobayashi ,&nbsp;Taito Fukushima ,&nbsp;Shuichi Mitsunaga ,&nbsp;Takaaki Furukawa ,&nbsp;Satoshi Hamauchi ,&nbsp;Makoto Ueno ,&nbsp;Junji Furuse","doi":"10.1016/j.ejca.2025.115424","DOIUrl":"10.1016/j.ejca.2025.115424","url":null,"abstract":"<div><h3>Background</h3><div>Liposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) improves survival in gemcitabine-refractory metastatic pancreatic cancer (PC) but requires a central venous port. S-1, an oral fluoropyrimidine with proven efficacy in PC, may replace 5-FU/LV in nal-IRI plus 5-FU/LV, potentially enhancing both convenience and antitumor effect.</div></div><div><h3>Methods</h3><div>This single-arm, open-label, phase 1/2 study included patients with histologically or cytologically confirmed adenocarcinoma, aged 20–80 years, an Eastern Cooperative Oncology Group performance status of 0–1, with metastatic disease, and refractory to gemcitabine-based treatment. The primary endpoint in phase 1 part was the frequency of dose-limiting toxicity (DLT) to nal-IRI plus S-1. The primary endpoint in phase 2 part was overall survival. This trial was registered in the Japan Registry of Clinical Trials database (jRCTs031210040).</div></div><div><h3>Results</h3><div>In phase 1 part, one patient with DLT was observed at nal-IRI 70 mg/m² (day 1) with S-1 80 mg/m²/day (day 1–7) in a 2-week cycle, establishing this as the recommended phase 2 dose (RP2D). Forty-nine patients from phase 1 (n = 6) and phase 2 part (n = 43) were treated with the RP2D, and their results were pooled. Median overall survival was 10.3 months (95 % confidence interval, 8.1–12.0 months). A confirmed partial response was achieved in 10 patients (20.4 %). The most frequent treatment-emergent adverse events were hypoalbuminemia (98.0 %), anemia (98.0 %), and anorexia (81.6 %). There were no treatment-related deaths.</div></div><div><h3>Conclusions</h3><div>This study demonstrated that nal-IRI plus S-1 exhibited promising efficacy and an acceptable safety profile in patients with metastatic PC refractory to gemcitabine-based treatment.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115424"},"PeriodicalIF":7.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin","authors":"Samy Belkaïd ,&nbsp;Emmanuel Ribereau-Gayon ,&nbsp;Sylvie Chabaud ,&nbsp;Julien Anriot ,&nbsp;Thibald Chalas ,&nbsp;Aude Fléchon ,&nbsp;Helen Boyle ,&nbsp;Armelle Vinceneux ,&nbsp;Frédéric Bérard ,&nbsp;Benoît You ,&nbsp;Gilles Freyer ,&nbsp;Sophie Darnis ,&nbsp;Sophie Tartas ,&nbsp;Mona Amini-Adle","doi":"10.1016/j.ejca.2025.115427","DOIUrl":"10.1016/j.ejca.2025.115427","url":null,"abstract":"<div><h3>Aim of the study</h3><div>The antibody-drug conjugate enfortumab vedotin (EV) received approval in patients with metastatic urothelial carcinoma (mUC). EV-related cutaneous toxicities are frequently reported, whether EV-related AEs association with survival may exist is still unknown. We aim to report the association between cutaneous toxicities and survival in patients receiving EV.</div></div><div><h3>Methods</h3><div>This retrospective study enrolled patients treated with monotherapy EV from two oncology centers, followed up for at least 3-months, and data collection demographics, treatments, toxicities, and outcomes. The primary endpoint was progression-free survival (PFS) in patients experiencing cutaneous toxicities or not. Overall survival (OS) was the secondary endpoint.</div></div><div><h3>Results</h3><div>Data from 63 patients treated with EV from July 19, 2019, to March 12, 2024, were collected. Among them, the 18 (28.6 %) patients experiencing any-grade cutaneous toxicities during EV treatment showed significantly longer median PFS (mPFS: 9.2 <em>vs</em>. 4.7 months, hazard ratio [HR] 0.35; p = 0.0041) and OS (mOS: not reached <em>vs</em>. 8.4 months, HR 0.38; p = 0.0253). The multivariate analysis showed a significant association of cutaneous toxicities with improved PFS (HR 0.40, p = 0.0319), and did not demonstrate significant association with OS even if tendency was kept (HR 0.41, p = 0.067).</div></div><div><h3>Conclusion</h3><div>These results support that patients experiencing any-grade cutaneous toxicity (skin rash) had a prolonged PFS. With the recent expansion of combined treatment using EV plus pembrolizumab in first-line in mUC patients, cutaneous toxicities need to be carefully monitored and optimized dedicated management provided, considering that cutaneous toxicity may be predictive of patient outcome.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115427"},"PeriodicalIF":7.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy","authors":"Federico Monaca ,&nbsp;Igor Gomez-Randulfe ,&nbsp;Ana Sofia Parreira ,&nbsp;Vito Longo ,&nbsp;Domenico Galetta ,&nbsp;Sara Pilotto ,&nbsp;Sara Polidori ,&nbsp;Ornella Cantale ,&nbsp;Alessio Stefani ,&nbsp;Emanuele Vita ,&nbsp;Paul Taylor ,&nbsp;Fabio Gomes ,&nbsp;Laura Cove-Smith ,&nbsp;Yvonne Summers ,&nbsp;Giampaolo Tortora ,&nbsp;Fiona Blackhall ,&nbsp;Silvia Novello ,&nbsp;Emilio Bria ,&nbsp;Raffaele Califano","doi":"10.1016/j.ejca.2025.115435","DOIUrl":"10.1016/j.ejca.2025.115435","url":null,"abstract":"<div><h3>Introduction</h3><div>Chemo-immunotherapy (CT-IO) has improved median overall survival (mOS) for patients with extensive-stage small cell lung cancer (ES-SCLC), but its association with immune-related adverse events (irAEs) remains unclear. While irAEs are often linked to better outcomes in other cancers, their prognostic value in ES-SCLC is not well understood.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of 399 consecutive ES-SCLC patients treated with first-line CT-IO between January 2020 and September 2024 across five European centres. Demographic and clinical data were collected. The impact of irAEs on progression-free survival (PFS) and overall survival (OS) was assessed using time-dependent Cox regression.</div></div><div><h3>Results</h3><div>The median follow-up was 15.0 months. The overall response rate was 80.3 %, with a median PFS of 6.0 months (95 % CI 5.7–6.3) and mOS of 10.4 months (95 % CI 9.2–11.6). IrAEs occurred in 30.6 % of patients, most commonly affecting the skin (11.0 %). The median time to onset of irAEs was 171 days. Patients with irAEs had significantly longer mPFS (10.8 vs. 5.3 months, p &lt; 0.001) and mOS (18.8 vs. 7.6 months, p &lt; 0.001) compared to those without. No significant difference was found between patients with grade ≥ 3 (n = 46) and &lt; 3 irAEs (n = 76). Multivariate analysis confirmed that irAEs were associated with improved OS (HR 0.64; 95 % CI 0.51–0.80, p &lt; 0.001) and showed a trend towards longer PFS (p = 0.028).</div></div><div><h3>Conclusion</h3><div>This is the largest retrospective study to demonstrate that irAEs are associated with improved clinical outcomes in ES-SCLC pts receiving 1 L CT-IO.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"221 ","pages":"Article 115435"},"PeriodicalIF":7.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the 9th Tumor, Node, and Metastasis Staging System for Patients with Surgically Resected Non-Small Cell Lung Cancer","authors":"Shia Kim ,&nbsp;Yura Ahn ,&nbsp;Geun Dong Lee ,&nbsp;Sehoon Choi ,&nbsp;Hyeong Ryul Kim ,&nbsp;Yong–Hee Kim ,&nbsp;Dong Kwan Kim ,&nbsp;Seung–Il Park ,&nbsp;Jae Kwang Yun","doi":"10.1016/j.ejca.2025.115436","DOIUrl":"10.1016/j.ejca.2025.115436","url":null,"abstract":"<div><h3>Introduction</h3><div>The ninth edition of the tumor, node, and metastasis (TNM) classification system was recently published by the International Association for the Study of Lung Cancer staging project. This study aimed to validate the ninth edition of the TNM staging system, and compare its discrimination power with that of the eighth edition.</div></div><div><h3>Methods</h3><div>Patients who had undergone complete resection with systematic lymph node dissection for non-small cell lung cancer (NSCLC) were included in this retrospective analysis. Significant differences among adjacent TNM stage groupings were identified using a Cox regression model. The concordance index (C-index), Akaike Information Criterion (AIC), and R² were calculated to assess the discriminatory power of the two classification systems.</div></div><div><h3>Results</h3><div>A total of 7429 patients (4325 male; interquartile range, 57–70 years) were analyzed. The median follow-up duration was 50.4 months (interquartile range, 18–69 months). Survival curves within adjacent stage groupings created according to the ninth edition exhibited significant differences for all groups when divided according to the clinical or pathological stage. Compared with that of the eighth edition, the ninth edition demonstrated an improved discriminatory ability, as evidenced by a higher C-index (0.769 vs. 0.767), lower AIC (26,820 vs. 26,851), and higher R² (0.164 vs. 0.160) values.</div></div><div><h3>Conclusions</h3><div>Compared to the eighth edition of the TNM staging system, the ninth edition demonstrated improved prognostic accuracy and superior discriminatory ability for clinical and pathological stages.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115436"},"PeriodicalIF":7.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenomic fingerprinting to identify associations between tumor morphology and epigenetic states","authors":"Shayan Monabbati ,&nbsp;Germán Corredor ,&nbsp;Tilak Pathak ,&nbsp;Craig Peacock ,&nbsp;Kailin Yang ,&nbsp;Shlomo Koyfman ,&nbsp;Peter Scacheri ,&nbsp;James Lewis Jr ,&nbsp;Anant Madabhushi ,&nbsp;Satish E. Viswanath ,&nbsp;Berkley Gryder","doi":"10.1016/j.ejca.2025.115429","DOIUrl":"10.1016/j.ejca.2025.115429","url":null,"abstract":"<div><h3>Introduction</h3><div>Measuring the chromatin state of a tumor provides a powerful map of its epigenetic commitments; however, as these are generally bulk measurements, it has not yet been possible to connect changes in chromatin accessibility to the pathological signatures of complex tumors. In parallel, recent advances in computational pathology have enabled the identification of spatial features and immune cells within oral cavity tumors and their microenvironment.</div></div><div><h3>Methods</h3><div>Here, we present pathogenomic fingerprinting (PaGeFin), a novel method that integrates morphological tumor features with chromatin states using ATAC-seq. This framework links spatial morphologic and epigenetic features, offering insights into tumor progression and immune evasion within and across tumors. Morphologic features describing spatial relationships between tumor and lymphocyte cells that are prognostic of oral cavity squamous cell carcinoma (OSCC) were identified through AI-driven pathology analysis. These pathomic features were spatially colocalized within the epigenome of 4 distinct sections of 4 OSCC tumors.</div></div><div><h3>Results</h3><div>These key features pinpointed chromatin regions responsible for critical immune cell function through peak locations and enrichment analysis, highlighting loci of CD27+ memory B cells, helper CD4+ T cells, and cytotoxic CD8 naïve T cells that likely drive morphologic changes in the distribution of lymphocytes in the tumor microenvironment and promote aggressive tumor behavior. Gene Ontology analysis revealed that the <em>CTLA4, CD79A, CD3D,</em> and <em>CCR7</em> genes were embedded in these regions.</div></div><div><h3>Conclusion</h3><div>This computational approach is the first to assess the correlation between pathomic and epigenetic features in the context of cancer.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"221 ","pages":"Article 115429"},"PeriodicalIF":7.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium","authors":"Gennaro Ciliberto ,&nbsp;Ruggero De Maria ,&nbsp;Patrizio Giacomini ,&nbsp;Valentina Trapani ,&nbsp;Martina Betti ,&nbsp;Gabriele Bucci ,&nbsp;Simonetta Buglioni ,&nbsp;Lucia D’Auria ,&nbsp;Roberta De Angelis ,&nbsp;Arcangela De Nicolo ,&nbsp;Celia Dupain ,&nbsp;Nancy Frederickx ,&nbsp;Maurizio Genuardi ,&nbsp;Stefano Indraccolo ,&nbsp;Monika Kolanowska ,&nbsp;Luca Mazzarella ,&nbsp;Frederique Nowak ,&nbsp;Matteo Pallocca ,&nbsp;Jeanesse Scerri ,&nbsp;Alessandro Sgambato ,&nbsp;Christophe Le Tourneau","doi":"10.1016/j.ejca.2025.115433","DOIUrl":"10.1016/j.ejca.2025.115433","url":null,"abstract":"<div><h3>Introduction</h3><div>The CAN.HEAL consortium, comprising 47 cancer centers and academic institutions across 17 EU countries, has developed a set of recommendations for Molecular Tumor Boards (MTBs) to address the lack of standardized guidelines in personalized cancer medicine.</div></div><div><h3>Methods</h3><div>Over the past 2 years, through extensive collaboration and seven dedicated online meetings, CAN.HEAL experts developed consensus-based recommendations across 10 critical domains.</div></div><div><h3>Results</h3><div>The consortium agreed that MTBs’ primary role is to perform molecular and clinical assessments for patients requiring care beyond standard treatment. Core MTB composition should include medical oncologists, molecular biologists, pathologists, and bioinformaticians. Patient eligibility criteria should prioritize performance status, with flexibility for rare cases. Shared informed consent is crucial for sample collection, data use, and research. A two-tiered IT workflow, with minimal and maximal datasets, is recommended, along with a comprehensive decision support tool. These recommendations focus on genomic testing, acknowledging diversity of NGS assays and proposing general guidelines. MTB reports should be concise, with technical details provided in the molecular diagnostic report. Innovative approaches like the Drug Rediscovery Protocol support access to off-label therapies. Harmonized training for MTB members is essential to bridging knowledge gaps in this evolving field. Indicators are needed to assess MTB effectiveness over time. Expanding MTB benefits to underserved populations depends on creating a shared European MTB database.</div></div><div><h3>Conclusion</h3><div>Standardizing MTB practices represents a key step toward equitable access to personalized medicine and improved cancer care across Europe. Sustainable implementation requires coordinated EU efforts, and dynamic MTBs that continuously refine genomic-driven decisions within real-world contexts.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115433"},"PeriodicalIF":7.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143850094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study","authors":"Isotta Martha Magaton ,&nbsp;Eva Blondeaux ,&nbsp;Anne-Sophie Hamy ,&nbsp;Sabine Linn ,&nbsp;Rinat Bernstein-Molho ,&nbsp;Fedro A. Peccatori ,&nbsp;Alberta Ferrari ,&nbsp;Estela Carrasco ,&nbsp;Shani Paluch-Shimon ,&nbsp;Elisa Agostinetto ,&nbsp;Marta Venturelli ,&nbsp;Ines Maria Vaz Luis ,&nbsp;Kenny A. Rodriguez-Wallberg ,&nbsp;Hee Jeong Kim ,&nbsp;Kimia Sorouri ,&nbsp;Tiphaine Renaud ,&nbsp;Halle C.F. Moore ,&nbsp;Wanda Cui ,&nbsp;Jyoti Bajpa ,&nbsp;Christine Rousset-Jablonski ,&nbsp;Matteo Lambertini","doi":"10.1016/j.ejca.2025.115434","DOIUrl":"10.1016/j.ejca.2025.115434","url":null,"abstract":"<div><h3>Introduction</h3><div>Very limited data exist on assisted reproductive technology (ART) use in <em>BRCA1/2</em> carriers conceiving after breast cancer. This study aimed to investigate the safety of ART to achieve a pregnancy after breast cancer in <em>BRCA1/2</em> carriers.</div></div><div><h3>Methods</h3><div>This is an international, hospital-based, retrospective cohort study including <em>BRCA</em>1/2 carriers with a pregnancy after prior breast cancer diagnosis at ≤ 40 years of age between 2000 and 2020. Outcomes were compared between young <em>BRCA1/2</em> carriers who conceived using ART and those who conceived spontaneously.</div></div><div><h3>Results</h3><div>Among 543 <em>BRCA</em>1/2 carriers with a pregnancy after breast cancer, 436 conceived spontaneously and 107 using ART. Of 107 pregnancies achieved with ART, 45 (42.1 %) were obtained using oocytes/embryo cryopreserved at diagnosis, 33 (30.8 %) after controlled ovarian stimulation for in-vitro-fertilization/intracytoplasmic sperm injection or ovulation induction for intrauterine insemination or planned intercourse after anticancer treatments, 21 (19.6 %) after oocyte donation, while for 8 (7.5 %) patients type of ART was missing. Compared to patients in the no-ART group, those in the ART group were older at the time of conception, had more frequently hormone receptor-positive breast cancer and a longer median time from cancer diagnosis to conception. At a median follow-up of 5.2 years after conception, no apparent detrimental effect of ART on disease-free survival was observed (adjusted HR=0.72, 95 % CI 0.39–1.34).</div></div><div><h3>Conclusion</h3><div>In young <em>BRCA1/2</em> carriers with a pregnancy after breast cancer, ART use did not appear to be associated with increased risk of DFS events.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115434"},"PeriodicalIF":7.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143878907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current perspective on resectability in stage III locally advanced NSCLC – The thoracic surgeons’ view","authors":"Clemens Aigner ,&nbsp;Natalie Baldes ,&nbsp;Merjem Begic ,&nbsp;Fabian Doerr ,&nbsp;Mir Alireza Hoda ,&nbsp;Servet Bölükbas","doi":"10.1016/j.ejca.2025.115426","DOIUrl":"10.1016/j.ejca.2025.115426","url":null,"abstract":"<div><div>Surgical expertise is crucial in determining resectability. Due to differences in surgical expertise, cooperation with other surgical departments, and technical equipment available, a differentiation between “standard resectability” and “resectability with advanced technical requirements” can introduce a clear decision algorithm for interdisciplinary tumorboards. The current 2024 EORTC survey highlights areas with a lack of consensus on surgical indications in stage III NSCLC. T4 NSCLC with involvement of adjacent structures should be managed in high-volume, experienced centers following MDT discussion.</div><div>Future research should focus on refining selection criteria for surgery and optimize treatment strategies in patients with locally advanced NSCLC.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"221 ","pages":"Article 115426"},"PeriodicalIF":7.6,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes","authors":"Marta Fortuny ,&nbsp;Marta García-Calonge ,&nbsp;Óscar Arrabal ,&nbsp;Marco Sanduzzi-Zamparelli ,&nbsp;Andrés Castaño-García ,&nbsp;Enric Cascos ,&nbsp;Alicia Mesa ,&nbsp;Ana María Piedra-Cerezal ,&nbsp;Neus Llarch ,&nbsp;Gemma Iserte ,&nbsp;Marta Campos ,&nbsp;Melina González ,&nbsp;Aida Marsal ,&nbsp;Rebeca Lorca ,&nbsp;Manuel Rodríguez ,&nbsp;Ferran Torres ,&nbsp;María Varela ,&nbsp;María Reig","doi":"10.1016/j.ejca.2025.115404","DOIUrl":"10.1016/j.ejca.2025.115404","url":null,"abstract":"<div><h3>Introduction</h3><div>Immunotherapy-based combinations have revolutionized the first-line treatment for advanced hepatocellular carcinoma (HCC), improving overall survival (OS). However, these therapies are associated with adverse events (AEs), particularly cardiological complications and major adverse cardiovascular events (MACE), which may adversely affect outcomes. The influence of comorbid conditions such as arterial hypertension (AHT) and type 2 diabetes mellitus (T2DM) on the incidence and prognosis of cardiological AEs in HCC patients remains understudied.</div></div><div><h3>Methods</h3><div>This retrospective study included 109 HCC patients treated with atezolizumab-bevacizumab, tremelimumab-durvalumab, or durvalumab as first-line therapy at two Spanish medical centers from 2017–2023. Patients were stratified by comorbidities, AE incidence, and cardiological risk (CARDIOSOR scale). The primary endpoints were the incidence of treatment-modifying AEs and MACE, and their association with survival.</div></div><div><h3>Results</h3><div>Among the cohort, 50.5 % experienced AEs of special interest (AESI), with 34 % considered immune-related (irAE). MACE occurred in 7.3 % of patients, including myocarditis (3.7 %). The CARDIOSOR scale identified a higher risk of MACE in patients with AHT, T2DM, or both (OR: 5.07, p = 0.034). Early cardiological AEs were independently associated with worse OS (HR: 3.38, p = 0.04). Patients with both AHT and T2DM exhibited higher rates of MACE (16.7 %) and treatment discontinuation (25.9 %). The CARDIOSOR scale effectively stratified patients into high-risk groups, correlating with increased MACE rates and poor survival outcomes.</div></div><div><h3>Conclusions</h3><div>Comorbid conditions, particularly AHT and T2DM, amplify the risk of MACE and influence treatment discontinuation. The CARDIOSOR scale is a valuable tool for personalized risk assessment, guiding tailored therapeutic strategies. Integrating cardiovascular risk management into HCC care is crucial for optimizing both oncological and cardiovascular outcomes.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"221 ","pages":"Article 115404"},"PeriodicalIF":7.6,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program ‘iTHER’” [Eur J Cancer 175 (2022) 311–325]","authors":"Karin P.S. Langenberg ,&nbsp;Michael T. Meister ,&nbsp;Jette J. Bakhuizen ,&nbsp;Judith M. Boer ,&nbsp;Natasha K.A. van Eijkelenburg ,&nbsp;Esther Hulleman ,&nbsp;Uri Ilan ,&nbsp;Eleonora J. Looze ,&nbsp;Miranda P. Dierselhuis ,&nbsp;Jasper van der Lugt ,&nbsp;Willemijn Breunis ,&nbsp;Linda G. Schild ,&nbsp;Kimberley Ober ,&nbsp;Sander R. van Hooff ,&nbsp;Marijn A. Scheijde-Vermeulen ,&nbsp;Laura S. Hiemcke-Jiwa ,&nbsp;Uta E. Flucke ,&nbsp;Mariette E.G. Kranendonk ,&nbsp;Pieter Wesseling ,&nbsp;Edwin Sonneveld ,&nbsp;Jan J. Molenaar","doi":"10.1016/j.ejca.2025.115423","DOIUrl":"10.1016/j.ejca.2025.115423","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"221 ","pages":"Article 115423"},"PeriodicalIF":7.6,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}